TABLE 2.

Improvements in A1C Reduction and Postprandial Glucose Control for Lixisenatide as Add-On Therapy to Basal Insulin (25)

Lixisenatide (n = 146)Placebo (n = 154)P
Parameter
A1C reduction (%)
 Mean A1C at baseline8.58.5
 LS mean change at week 24−0.770.11
 LS mean difference vs. placebo (95% CI)−0.88 (−1.12 to −0.65)<0.0001
A1C goals at week 24 (%)
 A1C ≤6.5%17.81.3<0.0001
 A1C <7.0%35.65.2<0.0001
2-hour PPG (mg/dL)
n131142
 LS mean change at week 24−143.3−2.5
 LS mean difference vs. placebo (95% CI)−140.9 (−160.0 to −121.9)<0.0001
Glucose excursion (mg/dL)
n131142
 LS mean change at week 24−127.62.5
 LS mean difference vs. placebo (95% CI)−130.0 (−148.5 to −111.6)<0.0001
  • CI, confidence interval; LS, least squares; PPG, postprandial glucose.